Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
7
BJDX Quote, Financials, Valuation and Earnings
Last price:
$0.76
Seasonality move
:
-28.24%
Day range:
$0.78 - $0.89
52-week range:
$0.78 - $10.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.39x
Volume:
157.6K
Avg. volume:
105.1K
1-year change:
-79.49%
Market cap:
$1.5M
Revenue:
--
EPS (TTM):
-$32.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BJDX
Bluejay Diagnostics, Inc.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$16.6M | -- | 11.04% | -- | $36.00 |
|
MYO
Myomo, Inc.
|
$9.4M | -$0.11 | -13.8% | -1168.66% | $5.00 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BJDX
Bluejay Diagnostics, Inc.
|
$0.80 | -- | $1.5M | -- | $0.00 | 0% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7500 | $12.3077 | $204.4M | -- | $0.00 | 0% | 186.46x |
|
ELMD
Electromed, Inc.
|
$28.62 | $36.00 | $238.7M | 30.79x | $0.00 | 0% | 3.82x |
|
MYO
Myomo, Inc.
|
$0.93 | $5.00 | $35.8M | -- | $0.00 | 0% | 0.92x |
|
VNRX
VolitionRX Ltd.
|
$0.26 | $2.20 | $31.4M | -- | $0.00 | 0% | 17.54x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.77 | $1.50 | $107.8M | 75.49x | $0.00 | 0% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BJDX
Bluejay Diagnostics, Inc.
|
3.99% | -0.154 | 6.16% | 2.68x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BJDX
Bluejay Diagnostics, Inc.
|
-$31.6K | -$1.6M | -127.98% | -133.06% | -- | -$1.4M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Bluejay Diagnostics, Inc. vs. Competitors
-
Which has Higher Returns BJDX or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Bluejay Diagnostics, Inc.'s net margin of -12425.36%. Bluejay Diagnostics, Inc.'s return on equity of -133.06% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital BJDXBluejay Diagnostics, Inc.-- -$1.01 $3.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About BJDX or CATX?
Bluejay Diagnostics, Inc. has a consensus price target of --, signalling upside risk potential of 1599900%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Bluejay Diagnostics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Bluejay Diagnostics, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BJDXBluejay Diagnostics, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is BJDX or CATX More Risky?
Bluejay Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock BJDX or CATX?
Bluejay Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bluejay Diagnostics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BJDX or CATX?
Bluejay Diagnostics, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Bluejay Diagnostics, Inc.'s net income of -$1.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Bluejay Diagnostics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bluejay Diagnostics, Inc. is -- versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BJDXBluejay Diagnostics, Inc.-- -- -- -$1.6M CATXPerspective Therapeutics, Inc.186.46x -- $209K -$26M
-
Which has Higher Returns BJDX or ELMD?
Electromed, Inc. has a net margin of -- compared to Bluejay Diagnostics, Inc.'s net margin of 12.65%. Bluejay Diagnostics, Inc.'s return on equity of -133.06% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital BJDXBluejay Diagnostics, Inc.-- -$1.01 $3.8M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About BJDX or ELMD?
Bluejay Diagnostics, Inc. has a consensus price target of --, signalling upside risk potential of 1599900%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Bluejay Diagnostics, Inc. has higher upside potential than Electromed, Inc., analysts believe Bluejay Diagnostics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BJDXBluejay Diagnostics, Inc.0 0 0 ELMDElectromed, Inc.4 0 0 -
Is BJDX or ELMD More Risky?
Bluejay Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock BJDX or ELMD?
Bluejay Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bluejay Diagnostics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BJDX or ELMD?
Bluejay Diagnostics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Bluejay Diagnostics, Inc.'s net income of -$1.6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Bluejay Diagnostics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bluejay Diagnostics, Inc. is -- versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BJDXBluejay Diagnostics, Inc.-- -- -- -$1.6M ELMDElectromed, Inc.3.82x 30.79x $16.9M $2.1M
-
Which has Higher Returns BJDX or MYO?
Myomo, Inc. has a net margin of -- compared to Bluejay Diagnostics, Inc.'s net margin of -36.3%. Bluejay Diagnostics, Inc.'s return on equity of -133.06% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital BJDXBluejay Diagnostics, Inc.-- -$1.01 $3.8M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About BJDX or MYO?
Bluejay Diagnostics, Inc. has a consensus price target of --, signalling upside risk potential of 1599900%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 436.19%. Given that Bluejay Diagnostics, Inc. has higher upside potential than Myomo, Inc., analysts believe Bluejay Diagnostics, Inc. is more attractive than Myomo, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BJDXBluejay Diagnostics, Inc.0 0 0 MYOMyomo, Inc.4 0 0 -
Is BJDX or MYO More Risky?
Bluejay Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock BJDX or MYO?
Bluejay Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bluejay Diagnostics, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BJDX or MYO?
Bluejay Diagnostics, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Bluejay Diagnostics, Inc.'s net income of -$1.6M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Bluejay Diagnostics, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bluejay Diagnostics, Inc. is -- versus 0.92x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BJDXBluejay Diagnostics, Inc.-- -- -- -$1.6M MYOMyomo, Inc.0.92x -- $10.1M -$3.7M
-
Which has Higher Returns BJDX or VNRX?
VolitionRX Ltd. has a net margin of -- compared to Bluejay Diagnostics, Inc.'s net margin of -862.39%. Bluejay Diagnostics, Inc.'s return on equity of -133.06% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BJDXBluejay Diagnostics, Inc.-- -$1.01 $3.8M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About BJDX or VNRX?
Bluejay Diagnostics, Inc. has a consensus price target of --, signalling upside risk potential of 1599900%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that Bluejay Diagnostics, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Bluejay Diagnostics, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BJDXBluejay Diagnostics, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is BJDX or VNRX More Risky?
Bluejay Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock BJDX or VNRX?
Bluejay Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bluejay Diagnostics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BJDX or VNRX?
Bluejay Diagnostics, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Bluejay Diagnostics, Inc.'s net income of -$1.6M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Bluejay Diagnostics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bluejay Diagnostics, Inc. is -- versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BJDXBluejay Diagnostics, Inc.-- -- -- -$1.6M VNRXVolitionRX Ltd.17.54x -- $627.3K -$5.4M
-
Which has Higher Returns BJDX or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Bluejay Diagnostics, Inc.'s net margin of 3.93%. Bluejay Diagnostics, Inc.'s return on equity of -133.06% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital BJDXBluejay Diagnostics, Inc.-- -$1.01 $3.8M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About BJDX or XTNT?
Bluejay Diagnostics, Inc. has a consensus price target of --, signalling upside risk potential of 1599900%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Bluejay Diagnostics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Bluejay Diagnostics, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BJDXBluejay Diagnostics, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is BJDX or XTNT More Risky?
Bluejay Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock BJDX or XTNT?
Bluejay Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bluejay Diagnostics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BJDX or XTNT?
Bluejay Diagnostics, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Bluejay Diagnostics, Inc.'s net income of -$1.6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Bluejay Diagnostics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bluejay Diagnostics, Inc. is -- versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BJDXBluejay Diagnostics, Inc.-- -- -- -$1.6M XTNTXtant Medical Holdings, Inc.0.84x 75.49x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
